126 results
SC TO-C
MOR
Morphosys AG
6 Feb 24
Information about tender offer
4:52pm
for completing the transaction, the benefits sought to be achieved in the proposed transaction, the potential effects of the proposed transaction on Novartis … Pelabresib, or regarding expected benefits and success of, or potential future revenues from such products. You should not place undue reliance
SC TO-C
MOR
Morphosys AG
5 Feb 24
Information about tender offer
5:06pm
for completing the transaction, the benefits sought to be achieved in the proposed transaction, the potential effects of the proposed transaction on Novartis … Pelabresib, or regarding expected benefits and success of, or potential future revenues from such products. You should not place undue reliance
SC 14D9
EX-99
MOR
Morphosys AG
11 Apr 24
Tender offer solicitation
11:57am
during which the Executives renders his services to or for which the Executive receives monetary benefits from the Company. This cost coverage shall … further activities for the Company under continuation of the Executive’s benefits. Compensation claims pursuant to Sec. 5 paras. 1 and 2 and retirement
SC TO-C
EX-99.1
MOR
Morphosys AG
6 Feb 24
Information about tender offer
4:52pm
and the other conditions set forth in the business combination agreement), the expected timetable for completing the transaction, the benefits sought … approvals, new indications or labeling for the product candidates MorphoSys is developing, including Pelabresib, or regarding expected benefits
SC14D9C
EX-99.9
MOR
Morphosys AG
6 Feb 24
Written communication relating to third party tender offer
4:58pm
), the expected timetable for completing the transaction, the benefits sought to be achieved in the proposed transaction, the potential effects of the proposed … is developing, including Pelabresib, or regarding expected benefits and success of, or potential future revenues from such products. You should not place undue
SC TO-C
EX-99.2
fg96 be7wc0k
5 Feb 24
Information about tender offer
5:06pm
SC TO-C
EX-99.6
nggvtgmb520
2 Jun 21
Information about tender offer
5:20pm
SC TO-C
EX-99.5
y8fetmsp8o1u afei
2 Jun 21
Information about tender offer
5:20pm
SC14D9C
EX-99.1
r7ihen 3olu2hhae0o
6 Feb 24
Written communication relating to third party tender offer
4:58pm
SC TO-T
EX-99
v2t7czi3
11 Apr 24
Third party tender offer statement
6:01am
SC TO-C
EX-99.1
ikz1ea
5 Feb 24
Information about tender offer
5:06pm
6-K
EX-99.1
2txg iyih
11 Dec 23
MorphoSys’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study
11:26am
SC14D9C
EX-99.1
ifzt7ttntnowa
12 Feb 24
Written communication relating to third party tender offer
5:03pm
SC TO-C
EX-99.1
w1hkjd6w8tlt314vs
2 Jun 21
Information about tender offer
5:20pm
6-K
EX-99.2
w5mui5hi 7dflsk
2 Jun 21
Current report (foreign)
12:06pm
6-K
EX-99.1
elv 5vkkd
21 Nov 23
Topline Results Phase 3 MANIFEST-2 Study Pelabresib in First-Line Myelofibrosis November 2023 Gail, Living with Myelofibrosis since 2018
10:08am
6-K
EX-99.1
xlw1zxctng w9u
13 Jun 22
Current report (foreign)
4:07pm